Building on a track record of entrepreneurial DNA and decades of company-building success, we are uniquely positioned to identify breakthrough disruptive technologies and to transform them into leading businesses.
Prof. Nava Zisapel
Co-Founder and Chairperson
Prof. Zisapel is Founder and Chief Scientific Officer of Neurim Pharmaceuticals, Ltd. She is a full professor at Tel-Aviv University with a specialization in Neuro-biochemistry and holds the Michael Gluck Chair in Neuropharmacology and ALS Research - USA. Prof. Zisapel holds a B.Sc. in Chemistry, a M.Sc. in Biochemistry and a Ph.D. in Biochemistry from Tel-Aviv University. She has authored, together with her students and other scientists, over 160 original research publications in peer-reviewed journals.
Mr. Zisapel is the Founder and President of the RAD-Bynet Group, whose unique philosophy inspired the Israeli government’s creation of its first incubator program. Mr. Zisapel has a successful three-decade track record of seed-stage investing, including the co-founding of Neurim Pharmaceuticals, Ltd., a privately held drug discovery and development company. Mr. Zisapel is a Member of the Board of Directors of numerous RAD-Bynet Group companies
Mr. Elad serves as legal counsel for RAD BioMed as a whole and for its investee companies.
With extensive experience in advising and supporting start-up companies, Mr. Elad consults with investee companies regarding corporate law, fundraising transactions, strategic partnerships, clinical trials, licensing, and other commercial transactions.
He holds a B.A. in Social Sciences from the Hebrew University in Jerusalem and an L.L.B. degree from Tel Aviv University and has been a member of the Israeli Bar Association since 1996.
Business Development Manager
Carmi Zisapel serves as business development manager of RAD BioMed private accelerator.
Since joining Rad Biomed in 2014, she led two portfolio companies in the fields of nasogastric intubation and mitral valve repair.
Carmi holds a BSc degree in Electrical Engineering from the Technion.